We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Research and Markets Announces the Addition of High-Throughput Screening in Drug Discovery

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Research and Markets Announces the Addition of High-Throughput Screening in Drug Discovery "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Research and Markets has announced the addition of High-Throughput Screening in Drug Discovery to their offering.

This book is designed as a professional guide for compound screening in pharmaceutical research and chemical biology.

It discusses the rationale behind "intelligent" screening approaches and presents current methods and technologies for assaying bioactive molecules in a high-throughput situation.

In addition, it treats in detail the analysis of the date generated in the assay and chemoinformatics support for high-throughput data management - a facet that is often neglected but is of tremendous practical importance.

With its focus on bioanalysis and chemical biology, the book will be part of our rapidly growing cluster in this area.

Discover the latest improvements to compound screening in pharmaceutical research and chemical biology, including the chemoinformatic tools needed for proper data evaluation. With contributions from leading pharmaceutical companies in Europe and the US.

Contents Include:

Chemical Genetics (C. Shamu, Harvard University)

High-Throughput Screening for Targeted Drug Discovery (J. Huser, Bayer Healthcare)

Laboratory Automation (J. Comley, Cambridge, UK)

Binding Assays (L. Mayr, Novartis Pharma)

Cell-based Assays (S. Rees, GlaxoSmithKline)

Biochemical Assays (W. Mallender, Millennium Pharmaceuticals)

High-Content Screening (P. Lipp, University of Homburg/Saar)

Handling and Management of Primary Assay Data (H. Gubler, Novartis Pharma)

Chemoinformatic Tools for HTS Data Analysis (S. Mundt, Bayer HealthCare)

Efficient Use of Compound Libraries: Random Screening vs. Focused Libraries (M. Beck, Bayer CropScience)

Data Mining Using Cell-Based Assay Results (J. Caldwell, Novartis Institute)